{"classes":[{"categories":[{"measurements":[{"comment":"The upper 95% CI was not estimable due to insufficient events to determine the upper confidence boundary.","groupId":"OG000","lowerLimit":"5.49","upperLimit":"NA","value":"6.01"},{"groupId":"OG001","lowerLimit":"7.03","upperLimit":"11.70","value":"8.25"},{"comment":"The upper 95% CI was not estimable due to insufficient events to determine the upper confidence boundary.","groupId":"OG002","lowerLimit":"4.14","upperLimit":"NA","value":"4.76"},{"comment":"The upper 95% CI was not estimable due to insufficient events to determine the upper confidence boundary.","groupId":"OG003","lowerLimit":"5.06","upperLimit":"NA","value":"6.83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"description":"OS was defined as time since the starting date of the combination therapy until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-small cell lung cancer received selinexor 60 mg orally QW and docetaxel 75 mg/m\\^2 IV for every 3 weeks until PD or intolerable toxicity.","id":"OG000","title":"Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel"},{"description":"Participants with colorectal cancer received selinexor 80 mg orally QW and pembrolizumab 200 mg IV every 3 weeks until PD or intolerable toxicity.","id":"OG001","title":"Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab"},{"description":"Participants with colorectal cancer received selinexor 40 mg orally on Days 1, 3, 15 and 18 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\\^2; leucovorin 400 mg/m\\^2; 5- fluorouracil (5-FU) 400 mg/m\\^2 bolus then 5-FU 2400 mg/m\\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) until PD or intolerable toxicity up to 25 months.","id":"OG002","title":"Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1)"},{"description":"Participants with colorectal cancer received selinexor 80 mg orally on Days 1 and 15 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\\^2; leucovorin 400 mg/m\\^2; 5-FU 400 mg/m\\^2 bolus then 5-FU 2400 mg/m\\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) until PD or intolerable toxicity up to 25 months.","id":"OG003","title":"Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2)"}],"paramType":"MEDIAN","populationDescription":"MITT population included all participants who received at least 1 dose of selinexor in the combination therapy period.","reportingStatus":"POSTED","timeFrame":"Time since the starting date of combination therapy until death due to any cause (up to 25 months)","title":"Combination Therapy (Arms: A, B and C): Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}